Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | 161Tb-SibuDAB |
Synonyms | |
Therapy Description |
161Tb-SibuDAB is a radioligand therapy comprising the radionuclide Tb 161 linked to a PSMA-targeted ligand Sibu-DAB, which delivers radiation to PSMA-expressing tumor cells, potentially resulting in inhibition of tumor growth (PMID: 37442604). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
161Tb-SibuDAB | 161Tb SibuDAB|[161Tb}-SibuDAB|[161Tb}Tb-SibuDAB | 161Tb-SibuDAB is a radioligand therapy comprising the radionuclide Tb 161 linked to a PSMA-targeted ligand Sibu-DAB, which delivers radiation to PSMA-expressing tumor cells, potentially resulting in inhibition of tumor growth (PMID: 37442604). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06343038 | Phase I | Lutetium-177 PSMA-I&T 161Tb-SibuDAB | Targeted Radionuclide Therapy in Metastatic Prostate Cancer Using a New PSMA Ligand Radiolabelled With Terbium-161 (161Tb-SibuDAB) - Dose Identification/Escalation Phase Ia/b Study (PROGNOSTICS) | Recruiting | CHE | 0 |